Zometa is used to treat hypercalcemia resulting from cancer and multiple malignancies, malignant bone tumors, osteoporosis in men, treatment and prevention of osteoporosis in women after menopause, osteoporosis resulting from the use of glucocorticoids, Paget's disease (Behcet's disease). The active ingredient in
Zometa is zoledronic acid, which is a bisphosphonate derivative that works to prevent bone resorption by affecting osteoclasts, which are the cells responsible for bone resorption. This leads to a reduction in the rate of bone resorption and an indirect increase in bone density.